This HTML5 document contains 88 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00768/identifier/kegg-compound/
n22http://linked.opendata.cz/resource/AHFS/
n15http://linked.opendata.cz/resource/drugbank/company/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00768/identifier/pubchem-compound/
foafhttp://xmlns.com/foaf/0.1/
n11http://linked.opendata.cz/resource/drugbank/dosage/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00768/identifier/pubchem-substance/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00768/identifier/drugbank/
n23http://bio2rdf.org/drugbank:
n7http://linked.opendata.cz/resource/drugbank/drug/DB00768/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/patent/
n21http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n5http://linked.opendata.cz/resource/drugbank/drug/DB00768/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n13http://www.drugs.com/cdi/
n14http://www.rxlist.com/cgi/generic2/
n10http://linked.opendata.cz/resource/drugbank/property/
n28http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00768/identifier/wikipedia/
n17http://linked.opendata.cz/resource/atc/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00768/identifier/pharmgkb/
n16http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00768
rdf:type
n3:Drug
n3:description
Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells.
n3:dosage
n11:271B5CC0-363D-11E5-9242-09173F13E4C5 n11:271B5CC4-363D-11E5-9242-09173F13E4C5 n11:271B5CC1-363D-11E5-9242-09173F13E4C5 n11:271B5CC2-363D-11E5-9242-09173F13E4C5 n11:271B5CC3-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, Mukouyama A: Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002 Apr;88(4):379-97. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12046981 # Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA: The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996 Winter;12(4):389-400. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8951675 # Ohmori K, Hasegawa K, Tamura T, Miyake K, Matsubara M, Masaki S, Karasawa A, Urayama N, Horikoshi K, Kajita J, Hasegawa M, Taniguchi K, Komada T, Kawamoto Y: Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung. 2004;54(12):809-29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15646365 # Ohmori K, Ikemura T, Kobayashi H, Mukouyama A: [Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug] Nippon Yakurigaku Zasshi. 2001 Jul;118(1):51-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11496828 # Kaliner MA, Oppenheimer J, Farrar JR: Comprehensive review of olopatadine: the molecule and its clinical entities. Allergy Asthma Proc. 2010 Mar;31(2):112-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20406593
n3:group
approved
n3:halfLife
3 hours
n3:indication
For the treatment of ocular itching associated with allergic conjunctivitis.
n3:manufacturer
n15:271B5CBB-363D-11E5-9242-09173F13E4C5 n15:271B5CB9-363D-11E5-9242-09173F13E4C5 n15:271B5CBA-363D-11E5-9242-09173F13E4C5
owl:sameAs
n21:DB00768 n23:DB00768
dcterms:title
Olopatadine
adms:identifier
n5:4444528 n6:C07789 n7:0065-0271-05 n8:DB00768 n19:Olopatadine n25:46506025 n26:PA450698 n27:5281071
n3:mechanismOfAction
Olopatadine is a selective histamine H1 antagonist that binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors.
n3:packager
n15:271B5CB6-363D-11E5-9242-09173F13E4C5 n15:271B5CB7-363D-11E5-9242-09173F13E4C5 n15:271B5CB4-363D-11E5-9242-09173F13E4C5 n15:271B5CB5-363D-11E5-9242-09173F13E4C5 n15:271B5CB2-363D-11E5-9242-09173F13E4C5 n15:271B5CB3-363D-11E5-9242-09173F13E4C5 n15:271B5CB8-363D-11E5-9242-09173F13E4C5
n3:patent
n9:1337603 n9:6995186 n9:5116863 n9:2195094
n3:routeOfElimination
Elimination was predominantly through renal excretion.
n3:synonym
Olopatadin Opatanol Olopatadine Olopatadina Olopatadinum
n16:hasAHFSCode
n22:04-00-00
n3:salt
n3:synthesisReference
Thomas Bader, Hans-Ulrich Bichsel, Bruno Gilomen, Imelda Meyer-Wilmes, Mark Sundermeier, "Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof." U.S. Patent US20070232814, issued October 04, 2007.
foaf:page
n13:olopatadine-spray.html n14:olopat.htm n28:pat1633.shtml
n3:IUPAC-Name
n10:271B5CC9-363D-11E5-9242-09173F13E4C5
n3:InChI
n10:271B5CCF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n10:271B5CCE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n10:271B5CCB-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n10:271B5CCC-363D-11E5-9242-09173F13E4C5
n3:SMILES
n10:271B5CCD-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n10:271B5CC7-363D-11E5-9242-09173F13E4C5 n10:271B5CDF-363D-11E5-9242-09173F13E4C5
n3:logP
n10:271B5CE1-363D-11E5-9242-09173F13E4C5 n10:271B5CC8-363D-11E5-9242-09173F13E4C5 n10:271B5CC5-363D-11E5-9242-09173F13E4C5
n3:logS
n10:271B5CC6-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n17:R01AC08 n17:S01GX09
n3:H-Bond-Acceptor-Count
n10:271B5CD5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n10:271B5CD6-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n10:271B5CD0-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n10:271B5CD1-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n10:271B5CD3-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n10:271B5CD2-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n10:271B5CD4-363D-11E5-9242-09173F13E4C5
n3:absorption
Ophthalmic use of olopatadine usually does not produce measurable plasma concentrations.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
113806-05-6
n3:category
n3:containedIn
n18:271B5CBD-363D-11E5-9242-09173F13E4C5 n18:271B5CBE-363D-11E5-9242-09173F13E4C5 n18:271B5CBC-363D-11E5-9242-09173F13E4C5 n18:271B5CBF-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n10:271B5CDB-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n10:271B5CDD-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n10:271B5CDE-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n10:271B5CE0-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n10:271B5CDA-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n10:271B5CD9-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n10:271B5CDC-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n10:271B5CCA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n10:271B5CD7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n10:271B5CD8-363D-11E5-9242-09173F13E4C5